Last updated: March 13, 2026
What is NDC 00904-7454?
NDC 00904-7454 is a drug identified by the National Drug Code (NDC). It corresponds to Rituximab (Trade name: Rituxan). Rituximab is a monoclonal antibody used primarily to treat non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
Market Overview
Market Size and Revenue Expectations
The global Rituximab market was valued at approximately $5.8 billion in 2022. The compound annual growth rate (CAGR) is projected at 4.5% through 2030, driven by expanding indications, increasing prevalence of autoimmune disorders, and improved access in emerging markets.
Key Market Drivers
- Increasing indications: Rituximab's approval for multiple autoimmune conditions (e.g., rheumatoid arthritis, ITP, multiple sclerosis) broadens its market.
- Aging population: Higher incidence of relevant diseases among older adults.
- Biologic pipeline: Growing number of biosimilar competitors, expected to impact pricing and market share timelines.
Competitive Landscape
Major competitors include:
- Rituximab biosimilars: Several approved in the U.S. and EU, such as Truxima (Celltrion), Ruxience (Celltrion), and others.
- Alternative biologics: Obinutuzumab, ofatumumab, and newer agents targeting similar pathways.
- Refill and reimmunization trends: Increasing number of patients on maintenance therapy sustains demand.
Regulatory Environment
Rituximab’s patent expiration occurred in 2018 in the U.S., allowing biosimilars to enter the market. The FDA approved five biosimilars between 2018-2022, with continued approvals expected. Pricing pressure from biosimilars is significant but varies based on manufacturing agreements, reimbursement policies, and healthcare provider adoption.
Price Projections
Current Pricing Landscape
- Brand-name Rituximab (Rituxan): Approximately $4,700 to $7,200 per vial, depending on dosage and formulation.
- Biosimilars: Typically priced 15-30% lower than the reference product, averaging $3,100 to $5,900 per vial.
Price Trends and Outlook
| Year |
Estimated Brand Price per Vial |
Biosimilar Price per Vial |
Comments |
| 2022 |
$6,500 |
$4,200 |
Baseline prices in mature markets |
| 2023 |
$6,200 |
$3,900 |
Slight decrease amid biosimilar competition |
| 2025 |
$5,800 |
$3,600 |
Continued downward pressure |
| 2030 |
$5,000 |
$3,200 |
Projected stabilization with market adaptation |
Factors Influencing Price Decline
- Market saturation: Increased biosimilar penetration reduces demand for the originator.
- Reimbursement policies: Payor pressure favors lower prices and prefers biosimilars.
- Manufacturing efficiencies: As production scales, costs decline, further driving prices down.
- Regulatory policies: Some countries impose price caps or negotiate discounts.
Potential Upside Factors
- New FDA approvals: Additional indications could increase demand, stabilizing or elevating prices.
- Market exclusivity for biosimilars: Limited in some jurisdictions, delaying competition.
- Therapeutic advancements: Next-generation biologics or small molecules could replace or complement Rituximab, impacting prices.
Market Challenges
- Biosimilar market share competition: With multiple biosimilars, price erosion is ongoing.
- Reimbursement negotiations: Variability across regions affects achievable pricing.
- Manufacturing complexities: Biologics' production costs influence pricing and supply stability.
Regional Market Projections
| Region |
2022 Market Size (Billion USD) |
Key Trends |
| North America |
$3.2 |
Dominance due to high diagnosis rates and reimbursement |
| Europe |
$1.8 |
Rapid biosimilar uptake reducing prices |
| Asia-Pacific |
$0.8 |
Growing access and expanding indications; prices lower than Western markets |
Key Takeaways
- NDC 00904-7454 (Rituximab) has an established multibillion-dollar market, with growth driven by broader indications and aging populations.
- Biosimilar entrants have exerted downward pressure on prices, with projections indicating further declines over the next five years.
- Prices in the U.S. for originator biologics are approximately $6,000, with biosimilars offering discounts of 15-30%.
- The competitive landscape will shape market dynamics, with potential for price stabilization through new indications and patent protections.
- Regional differences significantly impact pricing and market penetration, especially in emerging markets.
FAQs
1. What factors most influence Rituximab's price drops?
Biosimilar competition, payor negotiations, and regulatory policies primarily drive reductions.
2. When will biosimilars take significant market share?
Majority market penetration is expected by 2025, depending on regional regulatory approvals and acceptance by clinicians.
3. How does indication expansion impact Rituximab prices?
New approved indications can increase demand, possibly stabilizing prices temporarily amid biosimilar competition.
4. Are there regions where Rituximab prices remain high?
Yes. North America and Western Europe maintain higher prices due to established reimbursement systems and less biosimilar penetration.
5. What is the outlook for Rituximab’s profitability?
Revenue may decline due to biosimilar competition, but brand loyalty and new indications could mitigate losses.
References
[1] EvaluatePharma. (2022). Rituximab Market Analysis.
[2] IQVIA. (2022). Global Biosimilar Market Report.
[3] FDA. (2022). Biosimilar Approvals and Market Entry.
[4] MarketsandMarkets. (2023). Biologics Market by Product and Region.
[5] U.S. Food and Drug Administration. (2022). Biosimilar Approval Summaries.
